Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04969263 · ClinicalTrials.gov registry record · Phase 2
COVID-19 Protection After Transplant Pilot Study
A Phase 2 study of Kidney Transplant Recipients, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT04969263 is a Phase 2 study of Kidney Transplant Recipients that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 81 participants, above the 58-participant average among 4 other Kidney Transplant Recipients trials with a reported enrollment target (40% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04969263, a Phase 2 study of Kidney Transplant Recipients, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who have higher antibody levels. What level of antibodies is necessary for protection is currently unknown. Inadequate antibody response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination has been described among kidney transplant recipients. The aim of this study is to elicit an antibody response to vaccination against SARS-CoV-2 in kidney transplant recipients who have failed to respond to two doses of either the Moderna COVID-19 vaccine or Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) vaccine.
Conditions Studied
Interventions
- BIOLOGICAL BNT162b2 vaccine (Pfizer/BioNTech)
- BIOLOGICAL mRNA-1273 vaccine (Moderna)
Study Locations (1)
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2021-08-10 |
| Est. Completion | 2023-03-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04969263
The ClinicalTrials.gov registry entry for NCT04969263 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 58-participant average among 4 other Kidney Transplant Recipients trials with a reported enrollment target (40% higher). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplant Recipients appearing as the primary indexed condition, and to 2 interventions - of which BNT162b2 vaccine (Pfizer/BioNTech) is the first listed.
NCT04969263 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04969263 about?
NCT04969263 is a clinical study titled "COVID-19 Protection After Transplant Pilot Study". Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who have higher antibody levels. What level of antibodies is necessary for p...
What is the current status of trial NCT04969263?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2021-08-10. Estimated completion is 2023-03-10.
What conditions does trial NCT04969263 study?
This clinical trial studies the following conditions: Kidney Transplant Recipients.
What interventions are being tested in trial NCT04969263?
The interventions under investigation include: BNT162b2 vaccine (Pfizer/BioNTech) (BIOLOGICAL), mRNA-1273 vaccine (Moderna) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04969263?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04969263 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant Recipients
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
COVID Protection After Transplant-Immunosuppression Reduction
COMPLETED · Phase 2
-
Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
RECRUITING · Phase 4
-
Pilot Trial of Supplemental Vitamin A and Nicotinamide
RECRUITING · Early Phase 1
-
Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.